Beam Therapeutics (BEAM) Non-Current Assets (2019 - 2026)

Beam Therapeutics (BEAM) has reported Non-Current Assets for 8 consecutive years, with $213.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets fell 2.49% year-over-year to $213.8 million; the TTM figure through Mar 2026 stood at $854.6 million (down 5.33% YoY), while the FY2025 annual figure was $212.5 million, down 5.84% from the prior year.
• Non-Current Assets advanced to $213.8 million in Q1 2026 per BEAM's latest filing, from $212.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $259.1 million in Q2 2023 and bottomed at $212.5 million in Q4 2025.
• Historically, Non-Current Assets has averaged $232.1 million across 5 years, with a median of $231.8 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets grew 23.52% — and 2024, when it declined 10.52%.
• Beam Therapeutics' Non-Current Assets stood at $248.8 million in 2022, then declined by 0.06% to $248.7 million in 2023, then slipped by 9.25% to $225.7 million in 2024, then slipped by 5.84% to $212.5 million in 2025, then rose by 0.64% to $213.8 million in 2026.
• Business Quant data shows BEAM's Non-Current Assets at $213.8 million in Q1 2026, $212.5 million in Q4 2025, and $212.5 million in Q3 2025.